Eli Lilly’s new top dealmaker explains how the company changed its approach to M&A now that it’s the most valuable pharmaceutical company in the world.

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly’s newly approved Foundayo pill on June 1.